Alliancebernstein L.P. bought a new position in shares of Assembly Biosciences (NASDAQ:ASMB) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 12,000 shares of the biopharmaceutical company’s stock, valued at approximately $543,000. Alliancebernstein L.P. owned 0.06% of Assembly Biosciences as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the business. Jennison Associates LLC raised its holdings in Assembly Biosciences by 19.6% during the 4th quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock worth $95,944,000 after buying an additional 347,025 shares during the period. BlackRock Inc. raised its holdings in Assembly Biosciences by 19.6% during the 4th quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock worth $48,784,000 after buying an additional 176,976 shares during the period. Emerald Advisers Inc. PA acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $8,673,000. JPMorgan Chase & Co. raised its holdings in Assembly Biosciences by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after buying an additional 11,412 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Assembly Biosciences by 29.3% during the 4th quarter. Geode Capital Management LLC now owns 167,425 shares of the biopharmaceutical company’s stock worth $7,575,000 after buying an additional 37,953 shares during the period. Hedge funds and other institutional investors own 76.17% of the company’s stock.
ASMB has been the topic of a number of recent research reports. B. Riley initiated coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a “neutral” rating and a $35.00 price objective on the stock. BidaskClub downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday, January 15th. ValuEngine upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Finally, Jefferies Group lifted their price objective on shares of Assembly Biosciences to $75.00 and gave the company a “buy” rating in a report on Thursday, March 8th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $58.00.
In other news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $56.37, for a total value of $56,370.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 3,000 shares of company stock worth $152,550 over the last quarter. 19.60% of the stock is owned by corporate insiders.
NASDAQ ASMB opened at $44.93 on Tuesday. Assembly Biosciences has a 12-month low of $18.60 and a 12-month high of $67.36. The company has a market capitalization of $915.85, a PE ratio of -18.64 and a beta of 0.74.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/12000-shares-in-assembly-biosciences-asmb-acquired-by-alliancebernstein-l-p.html.
Assembly Biosciences Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences (NASDAQ:ASMB).
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.